Shutdown thrusts Gossamer Bio onto a rarely used path for fixed-price IPO
From day 1 Gossamer has always been a biotech in a hurry. And they’re not about to let a little thing like a government shutdown stymy their plans for an IPO.
As the partial US government shutdown continues to paralyze the SEC, Gossamer Bio has elected to use a rare and riskier method to make the leap into Nasdaq. The biotech is foregoing the typically lengthy SEC review of their prospectus to greenlight the listing in favor of enabling their registration by locking in their IPO price 20 days before making a market debut.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
